Facebook
Messenger
Twitter
LinkedIn
Email
Printadagrasib
Research on adagrasib has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations.
Mayo Clinic Comprehensive Cancer Center Blog
News, information and stories from Mayo Clinic’s cancer experts and patients
Mayo Clinic Cancer Center researchers identify promising drug to treat gastrointestinal cancers
Mayo Clinic Cancer Center researchers identify promising drug to treat gastrointestinal cancers